Forward-Looking Information and Non-U.S. GAAP Financial Measures Third Quarter 2025 Update Max K. Brodén Senior Executive Vice President CFO, Aflac Incorporated The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially ...

Health and life insurer Aflac topped Wall Street estimates for third-quarter profit and revenue on Tuesday, driven by investment gains and higher premium growth in its United States division. ...

Accessibility StatementSkip Navigation Total revenues were $4.7 billion in the third quarter of 2025, compared with $2.9 billion in the third quarter of 2024, primarily due to net investment gains of $275 million this quarter compared to net investment losses of $1.4 billion in the third quarter of 2024. Net earnings were $1.6 billion, or $3.08 per diluted share, compared with net losses of $93 million, or losses of $0.17 per diluted share a year ago. Net earnings in the third quarter of 2025 included net i ...

Aflac Incorporated's NYSE:AFL EPS is expected to decline by 16.7% year over year, despite a projected 52.2% increase in revenue.The company's financial metrics, including a P/E ratio of 23.61 and a debt-to-equity ratio of 0.33, highlight its market position and financial management.Analysts have revised the consensus EPS estimate upwards by 1.1% over the past month, indicating a positive reassessment of Aflac's financial health.Aflac Incorporated, listed on the NYSE under the symbol AFL, is a prominent play ...

The insurer saw sales double in three years after gambling on ads with a quacking duck. ...

Company Overview - Aflac Incorporated (AFL) is valued at $57.6 billion and is a leading provider of supplemental health and life insurance products, primarily operating in the United States and Japan [1] - The company was founded in 1955 and is headquartered in Columbus, Georgia, known for its iconic Aflac Duck marketing campaign [1] Earnings Expectations - Aflac is expected to announce its fiscal third-quarter earnings for 2025 on November 4, with analysts predicting a profit of $1.80 per share, down 16.7% from $2.16 per share in the same quarter last year [2] - For the full fiscal year, analysts expect an EPS of $6.91, a decrease of 4.2% from $7.21 in fiscal 2024, but a rebound is forecasted with a 6.4% increase to $7.35 in fiscal 2026 [3] Stock Performance - Aflac's stock has declined by 6.3% over the past year, underperforming the S&P 500 Index's 14.1% gains and the Financial Select Sector SPDR Fund's 9.6% gains during the same period [4] - On October 14, Aflac shares rose by 1.1% after Bank of America Securities analyst Joshua Shanker reaffirmed a "Buy" rating with a price target of $130 [5] Analyst Ratings - The consensus opinion on Aflac stock is cautious, with an overall "Hold" rating; out of 17 analysts, two recommend a "Strong Buy," one a "Moderate Buy," 11 a "Hold," and three a "Strong Sell" [6] - The average analyst price target for Aflac is $108.57, indicating a marginal upside from current levels [6]

Core Insights - Aflac Incorporated (NYSE:AFL) is recognized as one of the Top 15 Growth Stocks for Long-Term Investors [1] - The company has a significant presence in the Japanese market, which is crucial for its overall performance [2] Group 1: Financial Performance - In Q2 2025, Aflac Japan reported net earned premiums of ¥254.6 billion, reflecting a 23.2% year-over-year increase in sales [2] - The growth was largely attributed to the success of the new cancer insurance product, Miraito [2] Group 2: Strategic Focus - Aflac is prioritizing innovation, product development, and the expansion of its distribution network through strategic partnerships [3] - The company aims to strengthen its distribution channels and enhance its product portfolio to meet changing customer needs [3] Group 3: Dividend Policy - Aflac is recognized as a dividend aristocrat, having increased dividends for 42 consecutive years [4] - The current quarterly dividend is $0.58 per share, with a dividend yield of 2.09% as of October 12 [4]

Core Insights - Dividend growth stocks remain attractive for long-term investors due to their potential for consistent returns and lower volatility compared to high-growth companies [1][2][3] - Companies that regularly increase dividends are perceived as financially stable and often have strong competitive positions, making them appealing to risk-conscious investors [2][3] Methodology - The article identifies 15 dividend aristocrats, companies that have raised dividends for 25 consecutive years or more, with yields above 2% as of October 12 [5] Company Highlights - **Aflac Incorporated (NYSE:AFL)**: - Dividend yield of 2.09% as of October 13, with a focus on supplemental health and life insurance, particularly in Japan [7][9] - Reported a 23.2% year-over-year increase in sales in Q2 2025, driven by a new cancer insurance product [7] - Has a 42-year history of increasing dividends, currently paying $0.58 per share [9] - **Cincinnati Financial Corporation (NASDAQ:CINF)**: - Dividend yield of 2.19% as of October 13, with a history of raising dividends every year since 1960 [10][13] - Maintains a strong presence in the US insurance industry, providing property and casualty coverage through independent agents [11] - Demonstrates solid financial discipline, with a 65-year streak of consecutive dividend increases [12][13] - **PPG Industries, Inc. (NYSE:PPG)**: - Dividend yield of 2.88% as of October 13, specializing in paints, coatings, and specialty materials [14][17] - Invested billions in acquisitions to drive growth while maintaining a balanced capital allocation approach [15] - Has increased dividends for 54 consecutive years, currently paying $0.87 per share [17]

Core Insights - Aflac Incorporated is a significant player in the insurance industry, particularly known for its supplemental health insurance products in the U.S. and cancer and medical insurance offerings in Japan [1] Group 1: Company Performance - Barclays has maintained an "Underweight" rating for Aflac, while increasing the price target to $102 from $100, despite the stock price being $112.93 at the time [2][5] - Aflac's stock has shown volatility, trading between $112.55 and $113.89, with a market capitalization of approximately $60.4 billion [4][5] - Over the past year, Aflac's stock reached a high of $115.44 and a low of $96.95, indicating fluctuations in performance [4] Group 2: Commitment to Policyholders - Aflac has introduced a grace period for premium payments for federal employees affected by the government shutdown, demonstrating its commitment to supporting policyholders during challenging times [3][5]

Core Insights - Aflac Incorporated will release its third quarter 2025 financial results on November 4, 2025, after market close [1] - A conference call to discuss the quarterly results is scheduled for November 5, 2025, at 8:00 a.m. (ET) [2] - Aflac is recognized as the No. 1 provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan [2] Financial Information - The company reported total revenues of $4.2 billion for the second quarter of 2025 [4] Corporate Recognition - Aflac has been included in the World's Most Ethical Companies by Ethisphere for 19 consecutive years and in Fortune's World's Most Admired Companies for 24 years [2] - The company became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been part of the Dow Jones Sustainability North America Index for 11 years [2]